Next batter up! Targeting cancers with KRAS-G12D mutations
- Author(s)
- Zeissig, MN; Ashwood, LM; Kondrashova, O; Sutherland, KD;
- Details
- Publication Year 2023-08-15,Volume 9,Issue #11,Page 955-967
- Journal Title
- Trends in Canceer
- Abstract
- KRAS is the most frequently mutated oncogene in cancer. Activating mutations in codon 12, especially G12D, have the highest prevalence across a range of carcinomas and adenocarcinomas. With inhibitors to KRAS-G12D now entering clinical trials, understanding the biology of KRAS-G12D cancers, and identifying biomarkers that predict therapeutic response is crucial. In this Review, we discuss the genomics and biology of KRAS-G12D adenocarcinomas, including histological features, transcriptional landscape, the immune microenvironment, and how these factors influence response to therapy. Moreover, we explore potential therapeutic strategies using novel G12D inhibitors, leveraging knowledge gained from clinical trials using G12C inhibitors.
- Publisher
- Cell Press
- Keywords
- Kras; Kras g12d; Mrtx1133; adenocarcinoma; tumor suppressor
- Research Division(s)
- Cancer Biology And Stem Cells
- PubMed ID
- 37591766
- Publisher's Version
- https://doi.org/10.1016/j.trecan.2023.07.010
- Open Access at Publisher's Site
https://doi.org/10.1016/j.trecan.2023.07.010- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-28 09:37:23
Last Modified: 2023-11-20 03:24:11